Literature DB >> 27038241

Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes.

A Lonardo1, C D Byrne2, S H Caldwell3, H Cortez-Pinto4, G Targher5.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27038241     DOI： 10.1002/hep.28584

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  28 in total

Review 1.  Role and effective therapeutic target of gut microbiota in NAFLD/NASH.

Authors:  Qun Liu; Shousheng Liu; Lizhen Chen; Zhenzhen Zhao; Shuixian Du; Quanjiang Dong; Yongning Xin; Shiying Xuan
Journal:  Exp Ther Med       Date:  2019-07-17       Impact factor: 2.447

2.  Astrocyte elevated gene-1 (AEG-1): a new potential therapeutic target for the treatment of nonalcoholic steatohepatitis (NASH).

Authors:  Qinglan Wang; Ekihiro Seki
Journal:  Hepatobiliary Surg Nutr       Date:  2018-02       Impact factor: 7.293

3.  MicroRNA-199a-3p attenuates hepatic lipogenesis by targeting Sp1.

Authors:  Yang Cheng; Li Huang; Jian Ping; Tianyang Chen; Jianjie Chen
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

4.  Rhubarb free anthraquinones improved mice nonalcoholic fatty liver disease by inhibiting NLRP3 inflammasome.

Authors:  Chao Wu; Yanqin Bian; Bingjie Lu; Dan Wang; Nisma Lena Bahaji Azami; Gang Wei; Feng Ma; Mingyu Sun
Journal:  J Transl Med       Date:  2022-06-28       Impact factor: 8.440

Review 5.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

Review 6.  Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.

Authors:  Min Seok Cho; Sang Yeol Kim; Ki Tae Suk; Byung-Yong Kim
Journal:  J Microbiol       Date:  2018-10-25       Impact factor: 3.422

7.  Identification of key genes in non‑alcoholic fatty liver disease progression based on bioinformatics analysis.

Authors:  Lin Li; Huabao Liu; Xiaoyu Hu; Yi Huang; Yanan Wang; Yansha He; Qingsong Lei
Journal:  Mol Med Rep       Date:  2018-04-05       Impact factor: 2.952

8.  Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD).

Authors:  Pegah Golabi; Maria Stepanova; Huong T Pham; Rebecca Cable; Nila Rafiq; Haley Bush; Trevor Gogoll; Zobair M Younossi
Journal:  BMJ Open Gastroenterol       Date:  2018-03-20

9.  A network pharmacology-based approach to explore the effects of Chaihu Shugan powder on a non-alcoholic fatty liver rat model through nuclear receptors.

Authors:  Huan Nie; Yuanjun Deng; Chuiyang Zheng; Maoxing Pan; Jiqian Xie; Yupei Zhang; Qinhe Yang
Journal:  J Cell Mol Med       Date:  2020-03-18       Impact factor: 5.310

Review 10.  An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease.

Authors:  Ke Pei; Ting Gui; Dongfang Kan; Huichao Feng; Yanqiang Jin; Ying Yang; Qian Zhang; Ziwei Du; Zhibo Gai; Jibiao Wu; Yunlun Li
Journal:  Biomed Res Int       Date:  2020-07-18       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.